PJ Online | News: MeReC Extra on heart failure therapy
The Pharmaceutical Journal
MeReC Extra on heart failure therapy
The benefits of using an angiotensin converting enzyme (ACE) inhibitor and aspirin in patients with heart failure and coronary heart disease outweigh the consequences of their possible interaction, concludes the latest issue of MeReC Extra (No 4). It says that although studies have found biochemical and haemodynamic effects suggesting that an interaction exists, evidence for this translating into a clinically significant effect remains weak.
The issue also looks at the implications of the Val-HeFT (valsartan heart failure trial) study that assessed the addition of valsartan to standard therapy in heart failure. A copy is included with this week's issue of The Journal sent to community and hospital pharmacists in England and Wales. It is also available on the National Prescribing Centre websites (www.npc.co.uk and nww.npc.ppa.nhs.uk).
Citation: The Pharmaceutical Journal URI: 20006557
Recommended from Pharmaceutical Press